Amgen Inc. closed $84.79 short of its 52-week high ($346.85), which the company achieved on July 25th.

Neither coffee drinking pattern was tied to more or less cancer-specific mortality.

Investors should also pay attention to any latest changes in analyst estimates for Amgen. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, ...

Truist lowered the firm’s price target on Amgen (AMGN) to $298 from $333 and keeps a Hold rating on the shares as part of a broader research ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Amgen (AMGN – Research Report), with a ...

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $258.59 which represents a decrease of $-2.63 or -1.01% from the prior close of $261.22. The stock opened at $259.05 and touched a low of ...

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

Pfizer is expanding its collaboration with the start-up PostEra, which applies artificial intelligence to medicinal chemistry ...

But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.